Published 3 years ago • loading... • Updated 3 years ago

Paxlovid is safe, effective and doesn’t cause ‘rebound,’ FDA says

Summary by Ground News

Pfizer’s antiviral COVID-19 treatment Paxlovid is safe and effective at treating adults with mild to moderate COVID-19 who are at high risk of progressing to severe disease, including hospitalization or death, according to a Food and Drug Administration (FDA) staff report.

42 Articles

Western Mass News

Center

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

3 years ago

Read Full Article

WAVE

Center

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

3 years ago

Read Full Article

WFSB

Center

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

3 years ago·Connecticut, United States

Read Full Article

KCRG

Center

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

3 years ago·Cedar Rapids, United States

Read Full Article

Live5News

Center

Paxlovid not linked to COVID rebound, FDA says

Clinical trial data has concluded that there is no clear association with a COVID-19 rebound.

3 years ago

Read Full Article

WPBF

Center

Paxlovid not linked to COVID-19 rebound, FDA says ahead of meeting to consider drug's full approval

Over 8 million people in the U.S. have received Paxlovid, a combination of the drugs nirmatrelvir and ritonavir, since it became available under emergency use authorization in December 2021.

3 years ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year